Amphastar Pharmaceuticals

Amphastar Pharmaceuticals develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal drug products. Its portfolio includes generic versions of epinephrine auto‑injectors, insulin formulations, glucagon emergency kits, and various hospital‑administered medications. The company also pursues proprietary products such as specialized drug‑delivery technologies and niche therapeutics. It serves primarily the United States market while distributing select products to international partners. Its operations span research and development, formulation science, and commercial manufacturing.

The source material does not provide explicit quantitative details about the company’s employee count, revenue, or manufacturing footprint. Therefore, specific size metrics are omitted to avoid speculation. What is known is that Amphastar is headquartered in Rancho Cucamonga, California, and its securities are traded on the NASDAQ under the ticker AMPH. This indicates a publicly traded status and a presence in the U.S. capital markets.

Amphastar concentrates on complex generic and proprietary products that require specialized formulation expertise, particularly in injectable and inhalation routes. The company maintains regulatory compliance with the U.S. Food and Drug Administration and adheres to current good manufacturing practice (cGMP) standards across its facilities. Its capabilities in developing difficult‑to‑manufacture molecules, such as peptide‑based drugs and combination products, represent a notable competency within the specialty generics sector. Additionally, the firm has experience navigating patent challenges and launching products shortly after exclusivity periods expire.

Amphastar Pharmaceuticals operates as an independent corporation; no parent company or subsidiary relationships are disclosed in the provided source material. Its governance includes a board of directors responsible for overseeing strategic direction and risk management. The ransomware incident disclosed in May 2020 highlighted the company’s reliance on legacy data systems and prompted a response that included containment, backup‑based recovery, and notification of affected individuals without payment of a ransom.